STERIS plc (NYSE: STE) has signed a definitive agreement to acquire Xodus Medical, a Pennsylvania-based specialty surgical products maker, for $2.1bn at closing.
The STERIS Xodus Medical acquisition is expected to close by 31 December 2026, financed mainly with debt, according to Seeking Alpha.
Tax benefit cuts the net price
STERIS said the deal will generate cash tax benefits with a net present value of roughly $300m, bringing the net purchase price down to approximately $1.8bn.
Up to $150m in additional earnout consideration is tied to performance targets Xodus must hit in calendar 2028, STERIS disclosed.
The EBIT number behind the price tag
STERIS pegs Xodus’s anticipated 2026 revenue at about $245m, with adjusted EBIT of roughly $135m, a figure first confirmed by the Associated Press.
That adjusted figure, however, starts from a smaller base. STERIS’s own release shows Xodus’s projected operating income for 2026 at $121m, with roughly $14m added back for one-off charges, substantially a terminated royalty arrangement. The $135m headline number is a non-GAAP construct, not the business’s underlying run-rate earnings.
Stephens analyst Steven Etoch called the transaction a tuck-in. ‘Net-net, this is a logical tuck-in that adds additional operating-room supplies to Steris’ healthcare business,’ he said, as reported by the Associated Press.
Xodus makes single-use operating-room items, including electrosurgical accessories, medication labels, anti-fog products for surgical lenses, and sharps-handling safety devices, the AP reported.
Shares at a 20-day high
STE shares traded at $218.895 as of 1400 UTC on 12 October, up 1.93% on the day and at a 20-day high, having climbed 6.63% over the preceding 20 sessions. Volume ran 21% above the 20-day average.
FINRA short-sale data show no spike in bearish positioning ahead of the announcement: STE’s short-sale ratio ranged between 0.51 and 0.70 across the ten trading sessions to 9 October, consistent with routine trading rather than any build-up in short interest before the deal became public.
Financing backdrop
STERIS plans to fund the acquisition primarily with debt, a detail that puts the prevailing rate environment in focus. The 10-year US Treasury yield stood at 5.22% on 8 October, down slightly from 5.28% previously, according to FRED data from the Federal Reserve Bank of St Louis. The 2-year yield sat at 4.75%, against 4.77% prior, while the 10-year/2-year spread narrowed to 0.44 percentage points from 0.47. None of these moves is dramatic, but a debt-funded deal of this size means STERIS’s borrowing costs will sit close to current market levels rather than those of a looser-rate cycle.
STERIS said it will issue a revised fiscal 2027 outlook incorporating Xodus only once the acquisition has closed, leaving investors to assess the business on its stand-alone numbers in the meantime.
The company’s recent quarterly filings give some sense of the base onto which Xodus will be layered. Revenue for the quarter ended 30 June 2026 came in at $1.4927bn, against $1.4962bn in the prior quarter ended 31 December 2025 and $1.4603bn for the quarter ended 30 September 2025, according to filings with the SEC. Net income for the June quarter was $200.1m, continuing a steady climb from $177.4m a year earlier and $145.4m in the quarter ended 30 June 2024. Diluted earnings per share have moved from $1.46 in that June 2024 quarter to $1.79 in June 2025, with the most recently reported figure, for the quarter ended 31 December 2025, at $1.96.
Against that backdrop, Xodus’s projected $245m in annual revenue would represent a modest addition to a group now generating close to $1.5bn a quarter. The transaction’s size relative to STERIS’s balance sheet, and the reliance on debt rather than equity to fund it, are among the details likely to feature when the company next updates investors on integration plans and financing terms.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
